NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation
Status: | Completed |
---|---|
Conditions: | Atrial Fibrillation, Peripheral Vascular Disease, Cardiology |
Therapuetic Areas: | Cardiology / Vascular Diseases |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 10/26/2017 |
Start Date: | October 1, 2004 |
End Date: | March 1, 2011 |
This trial compares the safety and effectiveness of catheter ablation for PAF with
antiarrhythmic drug therapy. The investigational catheter being studied is the NAVISTAR®
THERMOCOOL® irrigated-tip catheter. At the time of this study, the NAVISTAR® THERMOCOOL®
catheter was FDA-approved for commercial distribution in the U.S. for treating patients with
Type I atrial flutter and drug refractory monomorphic ventricular tachycardia post myocardial
infarction. The catheter was approved for use in Europe for endocardial ablation for treating
cardiac arrhythmias.
antiarrhythmic drug therapy. The investigational catheter being studied is the NAVISTAR®
THERMOCOOL® irrigated-tip catheter. At the time of this study, the NAVISTAR® THERMOCOOL®
catheter was FDA-approved for commercial distribution in the U.S. for treating patients with
Type I atrial flutter and drug refractory monomorphic ventricular tachycardia post myocardial
infarction. The catheter was approved for use in Europe for endocardial ablation for treating
cardiac arrhythmias.
You may be eligible to participate in this study if you: Have failed to respond to drug
treatment for your AFib, or find the side effects of your medication intolerable.
Inclusion Criteria
- Patients with symptomatic PAF who have had three (3) AF episodes in the six (6) months
prior to randomization, one of which must be documented. Documentation may include
electrocardiogram (ECG), transtelephonic monitor (TTM), Holter monitor (HM), or
telemetry strip.
- Failure of at least one AAD for PAF [class I or III or AV nodal blocking agents such
as beta blockers (BB) and calcium channel blockers (CCB)] as evidenced by recurrent
symptomatic PAF, or intolerable side effects due to AAD.
- Signed Patient Informed Consent Form.
- Age 18 years or older.
- Able and willing to comply with all pre-, post- and follow-up testing and
requirements.
Exclusion Criteria
- Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or reversible
or non-cardiac cause.
- Previous ablation for atrial fibrillation.
- Patients on amiodarone therapy at any time during the previous six (6) months.
- AF episodes that last longer than 30 days and are terminated via cardioversion.
- Any valvular cardiac surgical procedure.
- CABG procedure within the last 180 days (six months).
- Awaiting cardiac transplantation or other cardiac surgery within the next 360 days (12
months).
- Documented left atrial thrombus on imaging (e.g. TEE).
- History of a documented thromboembolic event within the past one (1) year.
- Diagnosed atrial myxoma.
- Presence of implanted ICD.
- Significant pulmonary disease, (e.g. restrictive pulmonary disease, constrictive or
chronic obstructive pulmonary disease) or any other disease or malfunction of the
lungs or respiratory system that produces chronic symptoms.
- Significant congenital anomaly or medical problem that in the opinion of the
investigator would preclude enrollment in this study.
- Women who are pregnant (by history of menstrual period or pregnancy test if the
history is considered unreliable).
- Acute illness or active systemic infection or sepsis.
- Unstable angina.
- Myocardial infarction within the previous 60 days (two months).
- LVEF < 40%.
- History of blood clotting or bleeding abnormalities.
- Contraindication to anticoagulation (i.e. heparin or warfarin).
- Contraindication to CT/MRA procedure.
- Life expectancy less than 360 days (12 months).
- Enrollment in an investigational study evaluating another device or drug.
- Uncontrolled heart failure or NYHA class III or IV heart failure.
- Presence of intramural thrombus, tumor or other abnormality that precludes catheter
introduction or manipulation.
- Presence of a condition that precludes vascular access.
- Left atrial size ≥ 50 mm
We found this trial at
14
sites
Riverside Methodist Hospital Serving central Ohio since 1892, Riverside Methodist Hospital is consistently ranked one...
Click here to add this to my saved trials
Inova Fairfax Hospital Inova Fairfax Hospital, Inova's flagship hospital, is an 833-bed, nationally recognized regional...
Click here to add this to my saved trials
Univ of Rochester Medical Center One of the nation's top academic medical centers, the University...
Click here to add this to my saved trials
Johns Hopkins Hospital Patients are the focus of everything we do at The Johns Hopkins...
Click here to add this to my saved trials
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
Charleston, South Carolina 29425
843-792-1414
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Loyola University Medical Center Loyola University Health System is committed to excellence in patient care...
Click here to add this to my saved trials
Click here to add this to my saved trials
Florida Hospital Florida Hospital is one of the country
Click here to add this to my saved trials
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials